Remaining unboxed cells: before & after, case by case

The 14-document run grounds 16,126 of 16,335 corrected cells (98.72%), with both readback guards active. This document walks the seven residue cases: for each, the page as printed (before) and the corrected output rendered verbatim (after), with the cells that resolve without geometry highlighted in gold. In every case the output text handles the condition correctly — assembly, labeling, structure. The gold cells are missing geometry, never wrong values, and the coordinate readback confirmed no box sits on a different value.

Case	Cells	Standing
1 — Period header bands mid-table	38	Closable: generalize the stack closure to bands anywhere
2 — Labels wrapped across printed lines	34	Closable: widen the window a wrapped label may draw from
3 — Repeated wrapped twins	part of 52	Closable: combine twin pairing with fragment assembly
4 — Interleaved stacked headers	14	Closable: same band generalization as case 1
5 — Section totals, no printed label	7	Correct as-is: nothing printed to box
6 — Column names supplied for headerless tables	24	Correct as-is: nothing printed to box
7 — Bare '$' cells	32	Deliberate one-character rule; varies with the agent's structural choice

> Counting only cells that can be boxed in principle, coverage is 16,126 of 16,298 = 98.94%. The printed-but-unmatched residue is 172 cells, 1.05%, all warned by address in the run log.

Case 1 — Period header bands mid-table (38 cells corpus-wide)

Document 68178938, page 12, table 1 — 65 cells, 4 without a box in this extraction.

Two printed sections each carry their own stacked period band; the fragments print across several grid cells and rows (green). The output flattens both bands into complete compound headers. The mid-table band row (gold) is textually correct; its geometry is unresolved because the stack closure only operates in the top header region. Closable.

Before — on the page

Global Funds Transfer				
	Three Months Ended December 31,		**Year Ended December 31,**	
(Amounts in millions, except percentages)	**2022**	**2021**	**2022**	**2021**
Money transfer revenue	$ 303.4	$ 302.2	$ 1,190.3	$ 1,189.2
Bill payment revenue	8.8	9.1	35.6	39.6
Total revenue	312.2	311.3	1,225.9	1,228.8
Cost of revenue	169.5	170.4	668.2	683.2
Gross profit	$ 142.7	$ 140.9	$ 557.7	$ 545.6
Money transfer revenue change, constant currency	5%	2%	5%	6%
Financial Paper Products				
	Three Months Ended December 31,		**Year Ended December 31,**	
(Amounts in millions, except percentages)	**2022**	**2021**	**2022**	**2021**
Money order revenue	$ 11.9	$ 9.9	$ 44.1	$ 40.9
Official check revenue	18.0	3.4	40.1	13.9

After — the corrected output

Global Funds Transfer	Three Months Ended December 31, 2022	Three Months Ended December 31, 2021	Year Ended December 31, 2022	Year Ended December 31, 2021
Money transfer revenue	$ 303.4	$ 302.2	$ 1,190.3	$ 1,189.2
Bill payment revenue	8.8	9.1	35.6	39.6
Total revenue	312.2	311.3	1,225.9	1,228.8
Cost of revenue	169.5	170.4	668.2	683.2
Gross profit	$ 142.7	$ 140.9	$ 557.7	$ 545.6
Money transfer revenue change, constant currency	5%	2%	5%	6%
Financial Paper Products	Three Months Ended December 31, 2022	Three Months Ended December 31, 2021	Year Ended December 31, 2022	Year Ended December 31, 2021
Money order revenue	$ 11.9	$ 9.9	$ 44.1	$ 40.9
Official check revenue	18.0	3.4	40.1	13.9
Total revenue	29.9	13.3	84.2	54.8

Investment commissions expense	12.0	0.2	22.0	0.9
Gross profit (1)	$ 17.9	$ 13.1	$ 62.2	$ 53.9

Case 2 — Labels wrapped across printed lines (34 cells)

Document 68026754, page 14, table 1 — 182 cells, 4 without a box in this extraction.

A long row label prints on two lines (green). The output assembles each into one complete cell; every value on those rows carries a box, and only the assembled labels (gold) lack geometry. Closable.

Before — on the page

Net loss	$ (327,914)	$ (321,466)	$ (849,645)	$ (980,530)
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization, net of amortization of deferred grants	119,190	102,095	451,046	388,096
Deferred income taxes	2,291	28,316	2,291	9,607
Stock-based compensation expense	21,931	50,246	110,633	211,000
Interest on pass-through financing obligations	4,997	5,143	20,076	21,431
Reduction in pass-through financing obligations	(10,059)	(10,149)	(41,164)	(42,309)
Unrealized gain on derivatives	6,914		(184,904)	(21,686)
Other noncash items	27,283	18,953	53,651	82,286
Changes in operating assets and liabilities:				
Accounts receivable	545	28,046	(86,762)	(62,124)
Inventories	(194,810)	(62,300)	(277,085)	(223,774)
Prepaid and other assets	(95,092)	(103,557)	(378,807)	(377,505)
Accounts payable	55,221	(53,480)	40,458	66,932
Accrued expenses and other liabilities	(8,679)	5,242	64,122	33,195
Deferred revenue	93,509	28,563	227,297	78,195
Net cash used in operating activities	(304,673)	(284,348)	(848,793)	(817,186)
Investing activities:				
Payments for the costs of solar energy systems	(511,307)	(491,279)	(1,992,863)	(1,677,609)
Purchase of equity investment			(75,000)	
Purchases of property and equipment, net	(7,383)	3,064	(18,203)	(8,576)
Net cash provided by (used in) investing activities	(518,690)	(488,215)	(2,086,066)	(1,686,185)
Financing activities:				
Proceeds from line of credit	146,300	211,066	1,165,267	738,046
Repayment of line of credit	(147,109)	(209,284)	(871,175)	(757,640)
Proceeds from issuance of convertible senior notes, net of capped call transaction		2		372,000
Proceeds from issuance of non-recourse debt	1,047,200	495,735	3,428,830	2,186,990
Repayment of non-recourse debt	(632,708)	(103,045)	(1,799,428)	(856,091)

After — the corrected output

	Three Months Ended December 31,		Year Ended December 31,	
	2022	2021	2022	2021
Operating activities:				
Net loss	$ (327,914)	$ (321,466)	$ (849,645)	$ (980,530)
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization, net of amortization of deferred grants	119,190	102,095	451,046	388,096
Deferred income taxes	2,291	28,316	2,291	9,607
Stock-based compensation expense	21,931	50,246	110,633	211,000
Interest on pass-through financing obligations	4,997	5,143	20,076	21,431
Reduction in pass-through financing obligations	(10,059)	(10,149)	(41,164)	(42,309)
Unrealized gain on derivatives	6,914		(184,904)	(21,686)

Other noncash items	27,283	18,953	53,651	82,286
Changes in operating assets and liabilities:				
Accounts receivable	545	28,046	(86,762)	(62,124)
Inventories	(194,810)	(62,300)	(277,085)	(223,774)
Prepaid and other assets	(95,092)	(103,557)	(378,807)	(377,505)
Accounts payable	55,221	(53,480)	40,458	66,932
Accrued expenses and other liabilities	(8,679)	5,242	64,122	33,195
Deferred revenue	93,509	28,563	227,297	78,195
Net cash used in operating activities	(304,673)	(284,348)	(848,793)	(817,186)
Investing activities:				
Payments for the costs of solar energy systems	(511,307)	(491,279)	(1,992,863)	(1,677,609)
Purchase of equity investment			(75,000)	
Purchases of property and equipment, net	(7,383)	3,064	(18,203)	(8,576)
Net cash provided by (used in) investing activities	(518,690)	(488,215)	(2,086,066)	(1,686,185)
Financing activities:				
Proceeds from line of credit	146,300	211,066	1,165,267	738,046
Repayment of line of credit	(147,109)	(209,284)	(871,175)	(757,640)
Proceeds from issuance of convertible senior notes, net of capped call transaction		2		372,000
Proceeds from issuance of non-recourse debt	1,047,200	495,735	3,428,830	2,186,990
Repayment of non-recourse debt	(632,708)	(103,045)	(1,799,428)	(856,091)
Payment of debt fees	(20,712)	(11,036)	(62,994)	(53,793)
Proceeds from pass-through financing and other obligations, net	2,194	2,175	3,645	10,032
Repayment of pass-through financing obligation				(18,050)
Payment of finance lease obligations	(3,657)	(3,109)	(14,146)	(12,352)
Contributions received from noncontrolling interests and redeemable noncontrolling interests	489,243	338,400	1,414,793	1,238,732
Distributions paid to noncontrolling interests and redeemable noncontrolling interests	(65,528)	(54,430)	(217,633)	(196,466)
Acquisition of noncontrolling interest	(5,198)	(383)	(42,571)	(41,955)
Net proceeds related to stock-based award activities	10,308	12,791	32,863	36,141
Net cash provided by financing activities	820,333	678,882	3,037,451	2,645,594
Net change in cash and restricted cash	(3,030)	(90,690)	102,592	142,223
Cash and restricted cash, beginning of period	956,053	941,121	850,431	708,208
Cash and restricted cash, end of period	$ 953,023	$ 850,431	$ 953,023	$ 850,431

Case 3 — Repeated wrapped twins (part of 52 short-label cells)

Document 73195465, page 31, table 2 — 28 cells, 2 without a box in this extraction.

The same label appears twice, each occurrence wrapped across two lines (green). The output assembles both correctly (gold). Pairing wrapped twins to their printed order is the unresolved step. Closable.

Before — on the page

(in millions)	Hedged Item	Notional Amount	Original Maturity in Months
U.S. dollar floating to Euro fixed interest rate swaps	2021 U.S. Dollar Term Loan	$ 500.0	49
U.S. dollar interest rate caps	2021 U.S. Dollar Term Loan	$ 650.0	36
U.S. dollar to Euro currency swaps	2021 Senior Notes	$ 500.0	49
U.S. dollar currency forward contracts	Working Capital	$ 314.0	1-12

After — the corrected output

(in millions)	Hedged Item	Notional Amount	Original Maturity in Months
U.S. dollar floating to Euro fixed interest rate swaps	2021 U.S. Dollar Term Loan	$ 500.0	49
U.S. dollar interest rate caps	2021 U.S. Dollar Term Loan	$ 650.0	36
U.S. dollar to Euro currency swaps	2021 Senior Notes	$ 500.0	49
U.S. dollar currency forward contracts	Working Capital	$ 314.0	1-12
Floating to fixed interest rate swap(1)	Not Applicable	$ 315.0	60
Fixed to floating interest rate swap(1)	Not Applicable	$ 315.0	36

Case 4 — Side-by-side stacked headers, interleaved in the text stream (14 cells)

Document 72149870, page 9, table 3 — 24 cells, 3 without a box in this extraction.

Twin header stacks share three printed lines, so the page text reads 'Before After / Management Management / Fees (3) Fees (4)' and neither phrase is contiguous anywhere. The output assembles both labels exactly as the page shows (gold). Matching, not correction, is what misses them. Closable.

Before — on the page

(1) Excludes all facilities considered non-core and does not include federal stimulus revenue. For non-core definition, see Fourth Quarter 2022 Financial Supplemental posted in the Quarterly Supplements section of Omega s website.

Operator Census and Coverage (1)	Occupancy (2)	Coverage Data	
		Before Management Fees (3)	After Management Fees (4)
Twelve-months ended September 30, 2022	76.2 %	1.37x	1.04x
Twelve-months ended June 30, 2022	75.8 %	1.39x	1.06x
Twelve-months ended March 31, 2022	75.1 %	1.44x	1.10x
Twelve-months ended December 31, 2021	74.5 %	1.48x	1.14x

After — the corrected output

Operator Census and Coverage (1)	Occupancy (2)	Before Management Fees (3)	After Management Fees (4)
Twelve-months ended September 30, 2022	76.2 %	1.37x	1.04x
Twelve-months ended June 30, 2022	75.8 %	1.39x	1.06x
Twelve-months ended March 31, 2022	75.1 %	1.44x	1.10x
Twelve-months ended December 31, 2021	74.5 %	1.48x	1.14x
Twelve-months ended September 30, 2021	74.2 %	1.52x	1.18x

Case 5 — Section totals with no printed label (7 cells)

Document 68609235, page 133, table 1 — 115 cells, 7 without a box in this extraction.

Each section's totals row prints amounts with an empty label column (gold zone on the page). The output writes 'Total' there for readability (gold cells). Nothing is printed to box, so an empty box is the correct value. Unboxable in principle.

Before — on the page



After — the corrected output

	2022	2021	2020
Revenue from services:			
Pharmaceutical	$	$	$
Diagnostics	755,630	1,607,106	1,262,242
Corporate			
Total	$ 755,630	$ 1,607,106	$ 1,262,242
Revenue from products:			
Pharmaceutical	$ 142,845	$ 141,770	$ 119,952
Diagnostics			
Corporate			
Total	$ 142,845	$ 141,770	$ 119,952
Revenue from transfer of intellectual property and other:			
Pharmaceutical	$ 105,721	$ 25,842	$ 36,979
Diagnostics			16,240

Corporate			
Total	$ 105,721	$ 25,842	$ 53,219
Operating income (loss):			
Pharmaceutical	$ (12,961)	$ (19,051)	$ (43,519)
Diagnostics	(173,652)	98,067	138,922
Corporate	(39,640)	(60,266)	(37,689)
Total	$ (226,253)	$ 18,750	$ 57,714
Depreciation and amortization:			
Pharmaceutical	$ 68,618	$ 26,427	$ 29,001
Diagnostics	40,037	52,289	56,361
Corporate			
Total	$ 108,655	$ 78,716	$ 85,362
Loss from investment in investees:			
Pharmaceutical	$ (383)	$ (629)	$ (480)
Diagnostics			
Corporate			
Total	$ (383)	$ (629)	$ (480)
Revenues:			
U.S.	$ 783,207	$ 1,640,354	$ 1,317,766
Ireland	117,214	32,809	43,920
Chile	62,044	63,798	44,153
Spain	22,477	22,682	16,932
Israel	3,845	3,563	4,251
Mexico	14,546	11,005	7,865
Other	863	507	526
Total	$ 1,004,196	$ 1,774,718	$ 1,435,413

Case 6 — Column names for a table printed without a header row (part of 24 cells)

Document 73195465, page 2, table 1 — 38 cells, 2 without a box in this extraction.

The listing prints with no header row — the gold zone above the first row is empty on the page. The output supplies 'Item | Description' (gold) so the table is usable downstream. Neither word is printed as a header. Unboxable in principle.

Before — on the page

		Page Numbe
RT I		
m 1.	Condensed Consolidated Financial Statements	1
m 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	32
m 3.	Quantitative and Qualitative Disclosures About Market Risk	49
m 4.	Controls and Procedures	50
RT II		
m 1.	Legal Proceedings	52
m 1A.	Risk Factors	52
m 2.	Unregistered Sales of Equity Securities and Use of Proceeds	52

After — the corrected output

Item	Description	Page Number
PART I		
Item 1.	Condensed Consolidated Financial Statements	1
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	32
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	49
Item 4.	Controls and Procedures	50
PART II		
Item 1.	Legal Proceedings	52
Item 1A.	Risk Factors	52
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	52
Item 3.	Defaults Upon Senior Securities	52

Item 4.	Mine Safety Disclosures	52
Item 5.	Other Information	52
Item 6.	Exhibits	52

Case 7 — Bare '$' cells (most of 32 numerics)

Document 73195465, page 43, table 1 — 17 cells, 0 without a box in this extraction.

Camelot often keeps currency symbols (green) separate from their numbers. When the output preserves a standalone '$' column, those one-character cells are never span-matched, by design — a bare symbol would find a home inside any unrelated number. In this live run the agent joined the symbols to their numbers, so every cell resolved and nothing is gold.

Before — on the page

e following table details our restructuring and exit costs as reflected in the Condensed Consolidated Statements of Operations:

millions)		Three Months Ended March 31, 2023		Three Months Ended March 31, 2022
covery of lease receivables	$	(0.4)	$	(1.
cilities		1.5		8
nployee termination benefits		(0.6)		1
her				1
otal	$	0.5	$	9

e following table provides the details for the restructuring and exit cost liabilities:

	Employee

After — the corrected output

(in millions)	Three Months Ended March 31, 2023	Three Months Ended March 31, 2022
Recovery of lease receivables	$ (0.4)	$ (1.5)
Facilities	1.5	8.3
Employee termination benefits	(0.6)	1.8
Other		1.2
Total	$ 0.5	$ 9.8